Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Trial Profile

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Mycoses
  • Focus Registrational; Therapeutic Use
  • Acronyms FURI
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 03 Jan 2019 According to a SCYNEXIS media release, preliminary assessment by a Data Review Committee (DRC) of the first 20 completed patients was recently conducted and company expects to report top-line results by February 2019.
    • 09 Aug 2018 According to a SCYNEXIS media release, open-label FURI and CARES studies are designed for potential expedited regulatory approval via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).Also, preliminary data review from these trials is planned for the fourth quarter of 2018.
    • 07 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top